A newly filed Form 4 shows James B. Tananbaum, an insider at Latigo Biotherapeutics, Inc. (LTGO), purchased 140,000 shares of the company on the open market on August 10, 2026. The transaction was executed at $18.00 per share, for a total outlay of $2,520,000.00 out of the insider’s own funds.
Unlike option exercises or grants that don’t require personal capital, this filing is coded as an open-market purchase, meaning Tananbaum went into the market and bought shares alongside any other investor at the prevailing price. Following the transaction, Tananbaum’s beneficial ownership stands at 2,008,024 shares, held indirectly through a trust or entity structure rather than in a direct personal account.
What the Filing Shows
Form 4 filings are required whenever a company insider — an officer, director, or major shareholder — buys or sells shares of their own company, and they must be disclosed to the SEC within a short window of the trade. This particular filing lists Tananbaum’s role simply as ‘Insider,’ and the transaction is dated August 10, 2026, with the total position now exceeding two million shares on an indirect basis.
The size of the purchase, at roughly $2.5 million, represents a meaningful commitment of personal capital rather than a routine or automatic transaction. Because the shares are held indirectly, the beneficial ownership may run through a trust, LLC, or similar vehicle associated with Tananbaum, a structure that is common among insiders who also serve as founders or long-term strategic holders of biotech companies.
Context for Readers
Academic research on insider trading disclosures has found that clusters of open-market insider buying can, in aggregate and over long historical samples, correlate with periods of subsequent outperformance relative to the broader market. That said, this correlation is a statistical pattern observed across large datasets of filings and says nothing definitive about any single transaction, including this one. A single Form 4 reflects one individual’s decision at one point in time, shaped by considerations that are not disclosed in the filing itself, such as tax planning, compensation structuring, or personal financial goals.
Readers tracking Latigo Biotherapeutics should note that this filing is a matter of public record and part of the routine disclosure obligations that apply to company insiders. It does not constitute investment guidance, and interested readers can review the underlying filing directly through the SEC’s EDGAR database for full details on the transaction and Tananbaum’s reported holdings.
→ See all LTGO coverage on WhoIsBuyingNow
Source: original SEC Form 4 filing.